Mark Stenhouse, Chief Operating Officer at Prometheus Biosciences, Inc. (RXDX), bought 14,000 shares at $19.00 ($266K) on 2021-03-16, disclosed to the SEC on 2021-03-16.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| Filing → |
| EXAS | SELL | 2019-04-04 | $2.1M | — | Filing → |